Research ExplorerPublicationsMonitoring of the JAK2-V617F mutation by highly sensitive qu...

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

Standard

Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. / Kröger, Nicolaus; Badbaran, Anita; Holler, Ernst; Hahn, Joachim; Kobbe, Guido; Bornhäuser, Martin; Reiter, Andreas; Zabelina, Tatjana; Zander, Axel R.; Fehse, Boris.

In: BLOOD, Vol. 109, No. 3, 3, 2007, p. 1316-1321.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Badbaran, A, Holler, E, Hahn, J, Kobbe, G, Bornhäuser, M, Reiter, A, Zabelina, T, Zander, AR & Fehse, B 2007, 'Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.', BLOOD, vol. 109, no. 3, 3, pp. 1316-1321. <http://www.ncbi.nlm.nih.gov/pubmed/17018857?dopt=Citation>

APA

Kröger, N., Badbaran, A., Holler, E., Hahn, J., Kobbe, G., Bornhäuser, M., Reiter, A., Zabelina, T., Zander, A. R., & Fehse, B. (2007). Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. BLOOD, 109(3), 1316-1321. [3]. http://www.ncbi.nlm.nih.gov/pubmed/17018857?dopt=Citation

Vancouver

Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. BLOOD. 2007;109(3):1316-1321. 3.

Bibtex

@article{5ccdcefade1b4c1b895519d7544491b7,
title = "Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.",
abstract = "The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and might be a reliable marker to monitor residual disease after allogeneic stem cell transplantation. We describe a new, highly sensitive (>or= 0.01%) real-time polymerase chain reaction (PCR) to monitor and quantify V617F-JAK2-positive cells after dose-reduced allogeneic stem cell transplantation. After 22 allogeneic stem cell transplantation procedures in 21 JAK2-positive patients with myelofibrosis, 78% became PCR negative. In 15 of 17 patients (88%), JAK2 remained negative after a median follow-up of 20 months. JAK2 negativity was achieved after a median of 89 days after allograft (range, 19-750 days). A significant inverse correlation was seen for JAK2 positivity and donor-cell chimerism (r:-0.91, P",
author = "Nicolaus Kr{\"o}ger and Anita Badbaran and Ernst Holler and Joachim Hahn and Guido Kobbe and Martin Bornh{\"a}user and Andreas Reiter and Tatjana Zabelina and Zander, {Axel R.} and Boris Fehse",
year = "2007",
language = "Deutsch",
volume = "109",
pages = "1316--1321",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

RIS

TY - JOUR

T1 - Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

AU - Kröger, Nicolaus

AU - Badbaran, Anita

AU - Holler, Ernst

AU - Hahn, Joachim

AU - Kobbe, Guido

AU - Bornhäuser, Martin

AU - Reiter, Andreas

AU - Zabelina, Tatjana

AU - Zander, Axel R.

AU - Fehse, Boris

PY - 2007

Y1 - 2007

N2 - The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and might be a reliable marker to monitor residual disease after allogeneic stem cell transplantation. We describe a new, highly sensitive (>or= 0.01%) real-time polymerase chain reaction (PCR) to monitor and quantify V617F-JAK2-positive cells after dose-reduced allogeneic stem cell transplantation. After 22 allogeneic stem cell transplantation procedures in 21 JAK2-positive patients with myelofibrosis, 78% became PCR negative. In 15 of 17 patients (88%), JAK2 remained negative after a median follow-up of 20 months. JAK2 negativity was achieved after a median of 89 days after allograft (range, 19-750 days). A significant inverse correlation was seen for JAK2 positivity and donor-cell chimerism (r:-0.91, P

AB - The JAK2-V617F mutation occurs in about 50% of patients with myelofibrosis and might be a reliable marker to monitor residual disease after allogeneic stem cell transplantation. We describe a new, highly sensitive (>or= 0.01%) real-time polymerase chain reaction (PCR) to monitor and quantify V617F-JAK2-positive cells after dose-reduced allogeneic stem cell transplantation. After 22 allogeneic stem cell transplantation procedures in 21 JAK2-positive patients with myelofibrosis, 78% became PCR negative. In 15 of 17 patients (88%), JAK2 remained negative after a median follow-up of 20 months. JAK2 negativity was achieved after a median of 89 days after allograft (range, 19-750 days). A significant inverse correlation was seen for JAK2 positivity and donor-cell chimerism (r:-0.91, P

M3 - SCORING: Zeitschriftenaufsatz

VL - 109

SP - 1316

EP - 1321

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 3

M1 - 3

ER -